OBJECTIVES: To compare outcomes of antiretroviral therapy (ART) in South Africa, where viral load monitoring is routine, with those in Malawi and Zambia, where monitoring is based on CD4 cell counts. METHODS: We included 18,706 adult patients starting ART in South Africa and 80,937 patients in Zambia or Malawi. We examined CD4 responses in models for repeated measures and the probability of switching to second-line regimens, mortality and loss to follow-up in multistate models, measuring time from 6 months. RESULTS: In South Africa, 9.8% [95% confidence interval (CI) 9.1-10.5] had switched at 3 years, 1.3% (95% CI 0.9-1.6) remained on failing first-line regimens, 9.2% (95% CI 8.5-9.8) were lost to follow-up and 4.3% (95% CI 3.9-4.8) had died. In Malawi and Zambia, more patients were on a failing first-line regimen [3.7% (95% CI 3.6-3.9], fewer patients had switched [2.1% (95% CI 2.0-2.3)] and more patients were lost to follow-up [15.3% (95% CI 15.0-15.6)] or had died [6.3% (95% CI 6.0-6.5)]. Median CD4 cell counts were lower in South Africa at the start of ART (93 vs. 132 cells/μl; P < 0.001) but higher after 3 years (425 vs. 383 cells/μl; P < 0.001). The hazard ratio comparing South Africa with Malawi and Zambia after adjusting for age, sex, first-line regimen and CD4 cell count was 0.58 (0.50-0.66) for death and 0.53 (0.48-0.58) for loss to follow-up. CONCLUSION: Over 3 years of ART mortality was lower in South Africa than in Malawi or Zambia. The more favourable outcome in South Africa might be explained by viral load monitoring leading to earlier detection of treatment failure, adherence counselling and timelier switching to second-line ART.
OBJECTIVES: To compare outcomes of antiretroviral therapy (ART) in South Africa, where viral load monitoring is routine, with those in Malawi and Zambia, where monitoring is based on CD4 cell counts. METHODS: We included 18,706 adult patients starting ART in South Africa and 80,937 patients in Zambia or Malawi. We examined CD4 responses in models for repeated measures and the probability of switching to second-line regimens, mortality and loss to follow-up in multistate models, measuring time from 6 months. RESULTS: In South Africa, 9.8% [95% confidence interval (CI) 9.1-10.5] had switched at 3 years, 1.3% (95% CI 0.9-1.6) remained on failing first-line regimens, 9.2% (95% CI 8.5-9.8) were lost to follow-up and 4.3% (95% CI 3.9-4.8) had died. In Malawi and Zambia, more patients were on a failing first-line regimen [3.7% (95% CI 3.6-3.9], fewer patients had switched [2.1% (95% CI 2.0-2.3)] and more patients were lost to follow-up [15.3% (95% CI 15.0-15.6)] or had died [6.3% (95% CI 6.0-6.5)]. Median CD4 cell counts were lower in South Africa at the start of ART (93 vs. 132 cells/μl; P < 0.001) but higher after 3 years (425 vs. 383 cells/μl; P < 0.001). The hazard ratio comparing South Africa with Malawi and Zambia after adjusting for age, sex, first-line regimen and CD4 cell count was 0.58 (0.50-0.66) for death and 0.53 (0.48-0.58) for loss to follow-up. CONCLUSION: Over 3 years of ART mortality was lower in South Africa than in Malawi or Zambia. The more favourable outcome in South Africa might be explained by viral load monitoring leading to earlier detection of treatment failure, adherence counselling and timelier switching to second-line ART.
Authors: Andrew Boulle; Gilles Van Cutsem; Katherine Hilderbrand; Carol Cragg; Musaed Abrahams; Shaheed Mathee; Nathan Ford; Louise Knight; Meg Osler; Jonny Myers; Eric Goemaere; David Coetzee; Gary Maartens Journal: AIDS Date: 2010-02-20 Impact factor: 4.177
Authors: Olivia Keiser; Patrick MacPhail; Andrew Boulle; Robin Wood; Mauro Schechter; François Dabis; Eduardo Sprinz; Matthias Egger Journal: Trop Med Int Health Date: 2009-07-14 Impact factor: 2.622
Authors: Andrew N Phillips; Deenan Pillay; Alec H Miners; Diane E Bennett; Charles F Gilks; Jens D Lundgren Journal: Lancet Date: 2008-04-26 Impact factor: 79.321
Authors: Catherine Orrell; Guy Harling; Stephen D Lawn; Richard Kaplan; Matthew McNally; Linda-Gail Bekker; Robin Wood Journal: Antivir Ther Date: 2007
Authors: Ingrid Eshun-Wilson; Fiona Havers; Jean B Nachega; Hans W Prozesky; Jantjie J Taljaard; Michele D Zeier; Mark Cotton; Gary Simon; Patrick Soentjens Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2010-02-16
Authors: Matthias Egger; Ben D Spycher; John Sidle; Ralf Weigel; Elvin H Geng; Matthew P Fox; Patrick MacPhail; Gilles van Cutsem; Eugène Messou; Robin Wood; Denis Nash; Margaret Pascoe; Diana Dickinson; Jean-François Etard; James A McIntyre; Martin W G Brinkhof Journal: PLoS Med Date: 2011-01-18 Impact factor: 11.069
Authors: Mahlet Atakilt Woldetsadik; Kathy Goggin; Vincent S Staggs; Rhoda K Wanyenze; Jolly Beyeza-Kashesya; Deborah Mindry; Sarah Finocchario-Kessler; Sarah Khanakwa; Glenn J Wagner Journal: AIDS Behav Date: 2016-06
Authors: Aimalohi A Ahonkhai; Juliet Adeola; Bolanle Banigbe; Ifeyinwa Onwuatuelo; Abdulkabir B Adegoke; Ingrid V Bassett; Elena Losina; Kenneth A Freedberg; Prosper Okonkwo; Susan Regan Journal: J Int Assoc Provid AIDS Care Date: 2016-10-10
Authors: Janne Estill; Cindy Aubrière; Matthias Egger; Leigh Johnson; Robin Wood; Daniela Garone; Thomas Gsponer; Gilles Wandeler; Andrew Boulle; Mary-Ann Davies; Timothy B Hallett; Olivia Keiser Journal: AIDS Date: 2012-07-17 Impact factor: 4.177
Authors: A D Revell; D Wang; R Wood; C Morrow; H Tempelman; R L Hamers; G Alvarez-Uria; A Streinu-Cercel; L Ene; A M J Wensing; F DeWolf; M Nelson; J S Montaner; H C Lane; B A Larder Journal: J Antimicrob Chemother Date: 2013-03-13 Impact factor: 5.790
Authors: Steven J Reynolds; Joseph B Sempa; Agnes N Kiragga; Kevin Newell; Gertrude Nakigozi; Ronald Galiwango; Ron Gray; Thomas C Quinn; David Serwadda; Larry Chang Journal: AIDS Patient Care STDS Date: 2014-10-07 Impact factor: 5.078
Authors: Maxwell O Akanbi; Chad J Achenbach; Joe Feinglass; Babafemi Taiwo; Adamu Onu; Mai T Pho; Oche Agbaji; Phyllis Kanki; Robert L Murphy Journal: AIDS Res Hum Retroviruses Date: 2013-02-25 Impact factor: 2.205